Apricus Biosciences Receives Nasdaq Compliance Notice
(Thomson Reuters ONE) -
Company Intends to Request Hearing
SAN DIEGO, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that on November 30, 2016, the Company
received notice from the Nasdaq Listing Qualifications Staff (the "Staff") that
due to the Company's non-compliance with the $35 million market value of listed
securities ("MVLS") requirement, the Company was subject to delisting unless it
timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The
Company intends to timely request a hearing before the Panel, which request will
stay any delisting action by the Staff, pending the Panel's decision. At the
hearing, the Company will present its plan to regain compliance with the MVLS
requirement within the 180-day discretionary period available to the Panel,
ending May 29, 2017.
In accordance with the Nasdaq Listing Rules, the Company was previously granted
a 180-calendar day period within which to regain compliance with the MVLS
requirement, through November 29, 2016. In order to demonstrate compliance with
the MVLS requirement, the Company's MVLS must close at $35 million or more for a
minimum of 10 consecutive business days.
The Company is working on its plan to regain compliance with all applicable
requirements for continued listing on Nasdaq; however, there can be no assurance
that it will be able to timely do so.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros(®), for the treatment of erectile dysfunction, is approved in Canada and
certain countries in Europe, Latin America and the Middle East and is being
commercialized in several countries in Europe. In September 2015, Apricus in-
licensed the U.S. development and commercialization rights for Vitaros from
Allergan. Apricus' marketing partners for Vitaros include Recordati Ireland Ltd.
(Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals),
Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd.
Apricus currently has one active product candidate, RayVa((TM)), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros(®) is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act, as amended. Statements in this report
that are not purely historical are forward-looking statements. Such forward-
looking statements include, among other things: the Company's plans to request a
hearing before the Panel and whether the Company can demonstrate compliance with
the Nasdaq's continue listing rules, including with respect to MVLS. Actual
results could differ from those projected in any forward-looking statements due
to a variety of reasons that are outside of the Company's control, including,
but not limited to: the Panel's determination of the Company's request for
suspension of delisting; the Panel failing to approve the Company's plan to
regain compliance with the continued listing requirements; and other risks
identified by the Company in its reports filed with the Securities and Exchange
Commission ("SEC"). These forward-looking statements are made as of the date of
this press release, and the Company assumes no obligation to update the forward-
looking statements, or to update the reasons why actual results could differ
from those projected in the forward-looking statements. Readers are urged to
read the risk factors set forth in the Company's most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings
made with the SEC. Copies of these reports are available from the SEC's website
at www.sec.gov or without charge from the Company.
Contact:
Matthew Beck
mbeck(at)troutgroup.com
The Trout Group LLC
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.12.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 510374
Anzahl Zeichen: 5289
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences Receives Nasdaq Compliance Notice"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
